Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ciproterone acetate + ethinylestradiol is a fixed-dose combination oral medication containing two active ingredients: ciproterone acetate, a synthetic steroidal antiandrogen and progestogen, and ethinylestradiol, a synthetic estrogen. This combination is primarily used in women of reproductive age to treat conditions associated with androgen excess such as moderate to severe acne, seborrhea (oily skin), hirsutism (excessive hair growth), and symptoms of polycystic ovary syndrome (PCOS) when other treatments have failed. It also provides effective contraception during treatment for these conditions[1][4][6][7][8]. Mechanistically, ciproterone acetate acts by blocking androgen receptors and suppressing ovarian androgen production via negative feedback on the hypothalamic-pituitary-gonadal axis. Ethinylestradiol increases sex hormone-binding globulin (SHBG) levels, reducing free circulating androgens[5]. The combination regularizes menstrual cycles in PCOS patients. The product carries an increased risk of venous thromboembolism compared to some other contraceptives[7]. It should not be used solely for contraception or in women with contraindications to estrogen/progestogen therapy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ciproterone acetate + ethinylestradiol.